Montelukast%25252525252520levocetrizine

# Montelukast-Levocetirizine *Note: This combination is often prescribed as two separate agents. Fixed-dose combinations exist in some markets but are not FDA-approved in the U.S.* ## Overview A combination of a leukotriene receptor antagonist (montelukast) and a second-generation H1-antihistamine (levocetirizine). Used for synergistic management of allergic rhinitis and chronic urticaria. ## Primary Indications * Allergic rhinitis (seasonal and perennial). * Chronic idiopathic urticaria. * Adjunctive therapy for asthma (montelukast component). ## Adult Dosing * **Montelukast:** 10 mg orally once daily (usually in the evening). * **Levocetirizine:** 5 mg orally once daily (usually in the evening). ## Pediatric Dosing * **Ages 6–11 years:** * Montelukast: 5 mg chewable tablet once daily. * Levocetirizine: 2.5 mg once daily. * **Ages 2–5 years:** * Montelukast: 4 mg chewable tablet or oral granules once daily. * Levocetirizine: 1.25 mg (2.5 mL oral solution) once daily. * **Note:** Dosing varies by local protocol and product formulation availability. ## Dose Adjustments * **Renal Impairment (Levocetirizine):** CrCl 50–80 mL/min: 2.5 mg daily; CrCl 30–50 mL/min: 2.5 mg every 48 hours; CrCl 10–30 mL/min: 2.5 mg twice weekly. * **Hepatic Impairment:** No specific montelukast adjustment; use caution with severe hepatic impairment. ## Contraindications * Hypersensitivity to montelukast, levocetirizine, or cetirizine. * Severe renal impairment (CrCl <10 mL/min) or patients undergoing hemodialysis (levocetirizine). ## Adverse Effects * **Common:** Somnolence, fatigue, headache, nasopharyngitis, xerostomia (dry mouth). * **Serious (Montelukast):** Neuropsychiatric events (agitation, aggression, depression, suicidal ideation/behavior, sleep disturbances). * **Serious (General):** Rare cases of Churg-Strauss syndrome (eosinophilic granulomatosis with polyangiitis). ## Key Drug Interactions * **CNS Depressants:** Levocetirizine may potentiate sedative effects of alcohol, benzodiazepines, or opioids. * **CYP450 Inducers:** Phenobarbital, rifampin, or phenytoin may decrease montelukast concentrations. ## Monitoring * Monitor for neuropsychiatric changes (behavioral shifts, mood changes). * Monitor for systemic eosinophilia or vasculitic symptoms. * Assess for excessive sedation. ## Clinical Pearls * **FDA Boxed Warning:** The FDA recommends reserving montelukast for patients who do not respond to or cannot tolerate alternative therapies due to the risk of serious neuropsychiatric events. * **Timing:** Administering both drugs in the evening may enhance control of nocturnal rhinitis symptoms and capitalize on the sedative effect of levocetirizine to aid sleep. * **Formulation:** Ensure parents understand the difference between granules and chewable tablets for montelukast; granules can be mixed with soft foods (e.g., applesauce) but must be consumed within 15 minutes. *** **Educational Disclaimer:** This information is for educational purposes only. Always verify dosages, contraindications, and drug interactions against institutional protocols and current manufacturer prescribing information (e.g., DailyMed or drug databases) before prescribing or administering medication.